

Job F M Van Boven

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8314808/publications.pdf>

Version: 2024-02-01

147
papers

23,173
citations

100601

38
h-index

15253

130
g-index

151
all docs

151
docs citations

151
times ranked

42390
citing authors

#	ARTICLE	IF	CITATIONS
1	Personalizing the Use of a Intermittently Scanned Continuous Glucose Monitoring Device in Individuals With Type 1 Diabetes: A Cost-Effectiveness Perspective in the Netherlands (FLARE-NL 9). <i>Journal of Diabetes Science and Technology</i> , 2024, 18, 135-142.	1.3	2
2	Risk of neuropsychiatric adverse events associated with varenicline treatment for smoking cessation among Dutch population: A sequence symmetry analysis. <i>Pharmacoepidemiology and Drug Safety</i> , 2022, 31, 158-166.	0.9	4
3	Impact of Blood Eosinophil Variability in Asthma: A Real-Life Population Study. <i>Annals of the American Thoracic Society</i> , 2022, 19, 407-414.	1.5	11
4	Digital Health Technologies to Improve Medication Adherence and Treatment Outcomes in Patients With Tuberculosis: Systematic Review of Randomized Controlled Trials. <i>Journal of Medical Internet Research</i> , 2022, 24, e33062.	2.1	32
5	Prioritising primary care respiratory research needs: results from the 2020 International Primary Care Respiratory Group (IPCRG) global e-Delphi exercise. <i>Npj Primary Care Respiratory Medicine</i> , 2022, 32, 6.	1.1	9
6	Global Variability in Administrative Approval Prescription Criteria for Biologic Therapy in Severe Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 1202-1216.e23.	2.0	22
7	Electronic Inhaler Monitoring for Chronic Airway Disease: Development and Application of a Multidimensional Efficacy Framework. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 1189-1201.e1.	2.0	9
8	Improved health status of severe COPD patients after being included in an integrated primary care service: A prospective cohort study. <i>European Journal of General Practice</i> , 2022, 28, 66-74.	0.9	2
9	A Pharmacy-Based eHealth Intervention Promoting Correct Use of Medication in Patients With Asthma and COPD: Nonrandomized Pre-Post Study. <i>Journal of Medical Internet Research</i> , 2022, 24, e32396.	2.1	11
10	Medication availability and economic barriers to adherence in asthma and COPD patients in low-resource settings. <i>Npj Primary Care Respiratory Medicine</i> , 2022, 32, .	1.1	10
11	Can electronic monitoring with a digital smart spacer support personalised medication adherence and inhaler technique education in patients with asthma?: Protocol of the randomised controlled OUTERSPACE trial. <i>BMJ Open</i> , 2022, 12, e059929.	0.8	10
12	Medication Adherence Measurement Methods in Registration Trials Supporting the Approval of New Medicines: A Cross-sectional Analysis of Centralized Procedures in the European Union 2010-2020. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 1051-1060.	2.3	2
13	Aspiration Risk Factors, Microbiology, and Empiric Antibiotics for Patients Hospitalized With Community-Acquired Pneumonia. <i>Chest</i> , 2021, 159, 58-72.	0.4	24
14	Effectiveness of a targeted and tailored pharmacist-led intervention to improve adherence to antihypertensive drugs among patients with type 2 diabetes in Indonesia: A cluster randomised controlled trial. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 2032-2042.	1.1	14
15	Gaps in COPD Guidelines of Low- and Middle-Income Countries. <i>Chest</i> , 2021, 159, 575-584.	0.4	41
16	Economic evaluations of chronic obstructive pulmonary disease pharmacotherapy: how well are the real-world issues of medication adherence, comorbidities and adverse drug-reactions addressed?. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 923-935.	0.9	3
17	Work absence in patients with asthma and/or COPD: a population-based study. <i>Npj Primary Care Respiratory Medicine</i> , 2021, 31, 9.	1.1	8
18	Recovery from COVID-19: a sprint or marathon? 6-month follow-up data from online long COVID-19 support group members. <i>ERJ Open Research</i> , 2021, 7, 00141-2021.	1.1	79

#	ARTICLE	IF	CITATIONS
19	GINA 2020: Potential Impacts, Opportunities, and Challenges for Primary Care. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 1516-1519.	2.0	13
20	Biochemical Urine Testing of Medication Adherence and Its Association With Clinical Markers in an Outpatient Population of Type 2 Diabetes Patients: Analysis in the DIAbetes and LiFEstyle Cohort Twente (DIALECT). <i>Diabetes Care</i> , 2021, 44, 1419-1425.	4.3	11
21	Process Evaluation of Implementing a Pharmacist-Led Intervention to Improve Adherence to Antihypertensive Drugs Among Patients with Type 2 Diabetes in Indonesian Community Health Centers. <i>Frontiers in Pharmacology</i> , 2021, 12, 652018.	1.6	1
22	Maximizing Adherence and Gaining New Information For Your Chronic Obstructive Pulmonary Disease (MAGNIFY COPD): Study Protocol for the Pragmatic, Cluster Randomized Trial Evaluating the Impact of Dual Bronchodilator with Add-On Sensor and Electronic Monitoring on Clinical Outcomes. <i>Journal of Pragmatic and Observational Research</i> , 2021, Volume 12, 25-35.	1.1	5
23	Neuropsychiatric safety of varenicline in the general and COPD population with and without psychiatric disorders: a retrospective cohort study in a real-world setting. <i>BMJ Open</i> , 2021, 11, e042417.	0.8	5
24	Global burden of medication non-adherence in chronic obstructive pulmonary disease (COPD) and asthma: a narrative review of the clinical and economic case for smart inhalers. <i>Journal of Thoracic Disease</i> , 2021, 13, 3846-3864.	0.6	40
25	A Cross-Sectional Survey on Medication Management Practices for Noncommunicable Diseases in Europe During the Second Wave of the COVID-19 Pandemic. <i>Frontiers in Pharmacology</i> , 2021, 12, 685696.	1.6	24
26	Personalized Medication Adherence Management in Asthma and Chronic Obstructive Pulmonary Disease: A Review of Effective Interventions and Development of a Practical Adherence Toolkit. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 3979-3994.	2.0	26
27	Defining a Severe Asthma Super-Responder: Findings from a Delphi Process. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 3997-4004.	2.0	74
28	Challenges in the Implementation of Chronic Obstructive Pulmonary Disease Guidelines in Low- and Middle-Income Countries: An Official American Thoracic Society Workshop Report. <i>Annals of the American Thoracic Society</i> , 2021, 18, 1269-1277.	1.5	27
29	Editorial: Digital Tools to Measure and Promote Medication Adherence. <i>Frontiers in Medical Technology</i> , 2021, 3, 751976.	1.3	5
30	When biology meets behaviour: can medication adherence mask the contribution of pharmacogenetic effects in asthma?. <i>European Respiratory Journal</i> , 2021, 58, 2100304.	3.1	6
31	Strategies for the prevention, diagnosis and treatment of COPD in low- and middle- income countries: the importance of primary care. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 1563-1577.	1.0	17
32	European Network to Advance Best Practices and Technology on Medication Adherence: Mission Statement. <i>Frontiers in Pharmacology</i> , 2021, 12, 748702.	1.6	17
33	Clinical Characteristics, Treatment Patterns and Economic Burden of COPD in Kyrgyzstan: A FRESH AIR Study. <i>International Journal of COPD</i> , 2021, Volume 16, 2833-2843.	0.9	2
34	Clinical Value of Emerging Bioanalytical Methods for Drug Measurements: A Scoping Review of Their Applicability for Medication Adherence and Therapeutic Drug Monitoring. <i>Drugs</i> , 2021, 81, 1983-2002.	4.9	14
35	Prioritising respiratory research needs in primary care: results from the International Primary Care Respiratory Group (IPCRG) global e-Delphi exercise. , 2021, , .		2
36	Impact of blood eosinophil variability in asthma: a real-life population study. , 2021, , .		0

#	ARTICLE	IF	CITATIONS
37	Recovery from COVID-19: a sprint or marathon? 24-week follow-up data of online long COVID-19 peer support groups. , 2021, , .		0
38	Effects of an eHealth intervention promoting correct use of medication in patients with asthma and chronic obstructive pulmonary disease. , 2021, , .		1
39	Impact of Socioeconomic Status on Adult Patients with Asthma: A Population-Based Cohort Study from UK Primary Care. Journal of Asthma and Allergy, 2021, Volume 14, 1375-1388.	1.5	13
40	Prevalence and risk factors for <i>Enterobacteriaceae</i> in patients hospitalized with community-acquired pneumonia. Respiriology, 2020, 25, 543-551.	1.3	31
41	Trajectory Analyses of Adherence Patterns in a Real-Life Moderate to Severe Asthma Population. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 1961-1969.e6.	2.0	36
42	Benefits and harm of systemic steroids for short- and long-term use in rhinitis and rhinosinusitis: an EAACI position paper. Clinical and Translational Allergy, 2020, 10, 1.	1.4	110
43	Prevalence and Economic Burden of Respiratory Diseases in Central Asia and Russia: A Systematic Review. International Journal of Environmental Research and Public Health, 2020, 17, 7483.	1.2	7
44	A personalised screening strategy for diabetic retinopathy: a cost-effectiveness perspective. Diabetologia, 2020, 63, 2452-2461.	2.9	9
45	Switching Inhalers: A Practical Approach to Keep on UR RADAR. Pulmonary Therapy, 2020, 6, 381-392.	1.1	10
46	Implementing a context-driven awareness programme addressing household air pollution and tobacco: a FRESH AIR study. Npj Primary Care Respiratory Medicine, 2020, 30, 42.	1.1	5
47	Critical review of multimorbidity outcome measures suitable for low-income and middle-income country settings: perspectives from the Global Alliance for Chronic Diseases (GACD) researchers. BMJ Open, 2020, 10, e037079.	0.8	25
48	Burden and socioeconomics of asthma, allergic rhinitis, atopic dermatitis and food allergy. Expert Review of Pharmacoeconomics and Outcomes Research, 2020, 20, 437-453.	0.7	151
49	Interventions to improve medication adherence in tuberculosis patients: a systematic review of randomized controlled studies. Npj Primary Care Respiratory Medicine, 2020, 30, 21.	1.1	53
50	Prevalence and attributable health burden of chronic respiratory diseases, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Respiratory Medicine, the, 2020, 8, 585-596.	5.2	1,049
51	Bacterial etiology of community-acquired pneumonia in immunocompetent hospitalized patients and appropriateness of empirical treatment recommendations: an international point-prevalence study. European Journal of Clinical Microbiology and Infectious Diseases, 2020, 39, 1513-1525.	1.3	18
52	Prevalence of Seasonal Influenza Vaccination in Chronic Obstructive Pulmonary Disease (COPD) Patients in the Balearic Islands (Spain) and Its Effect on COPD Exacerbations: A Population-Based Retrospective Cohort Study. International Journal of Environmental Research and Public Health, 2020, 17, 4027.	1.2	4
53	Targeted and tailored pharmacist-led intervention to improve adherence to antihypertensive drugs among patients with type 2 diabetes in Indonesia: study protocol of a cluster randomised controlled trial. BMJ Open, 2020, 10, e034507.	0.8	7
54	Home initiation of chronic non-invasive ventilation in COPD patients with chronic hypercapnic respiratory failure: a randomised controlled trial. Thorax, 2020, 75, 244-252.	2.7	121

#	ARTICLE	IF	CITATIONS
55	<p>User Acceptability and Technical Robustness Evaluation of a Novel Smart Pill Bottle Prototype Designed to Support Medication Adherence</p>. Patient Preference and Adherence, 2020, Volume 14, 625-634.	0.8	25
56	Identification of important respiratory research themes relevant to primary care: qualitative analysis of round 1 of the 2020 International Primary Care Respiratory Group (IPCRG) Research Prioritisation Exercise. , 2020, , .		0
57	Towards Optimum Reporting of Pulmonary Effectiveness Databases and Outcomes (TORPEDO): a modified Delphi exercise to identify a core dataset for asthma and COPD studies. , 2020, , .		0
58	Prevalence and Etiology of Community-acquired Pneumonia in Immunocompromised Patients. Clinical Infectious Diseases, 2019, 68, 1482-1493.	2.9	116
59	Economic Impact of Reducing Inappropriate Inhaled Corticosteroids Use in Patients With Chronic Obstructive Pulmonary Disease: ISPOR's Guidance on Budget Impact in Practice. Value in Health, 2019, 22, 1092-1101.	0.1	12
60	Effects and acceptability of implementing improved cookstoves and heaters to reduce household air pollution: a FRESH AIR study. Npj Primary Care Respiratory Medicine, 2019, 29, 32.	1.1	24
61	Mapping 123 million neonatal, infant and child deaths between 2000 and 2017. Nature, 2019, 574, 353-358.	13.7	161
62	Costs of case-finding uncovered: time to revisit COPDâ€™s value pyramid?. Thorax, 2019, 74, 727-729.	2.7	7
63	Predicting shortâ€™and longâ€™term glycated haemoglobin response after insulin initiation in patients with type 2 diabetes mellitus using machineâ€™learning algorithms. Diabetes, Obesity and Metabolism, 2019, 21, 2704-2711.	2.2	17
64	The Hidden Story of Nonadherence with Asthma Therapy: For a Few Dollars More?. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 2307-2308.	2.0	2
65	Costs of clinical events in type 2 diabetes mellitus patients in the Netherlands: A systematic review. PLoS ONE, 2019, 14, e0221856.	1.1	8
66	Smart Medication Adherence Monitoring in Clinical Drug Trials: A Prerequisite for Personalised Medicine?. EClinicalMedicine, 2019, 15, 3-4.	3.2	16
67	ACO: Time to move from the description of different phenotypes to the treatable traits. PLoS ONE, 2019, 14, e0210915.	1.1	42
68	Prevalence and Characteristics of Asthmaâ€™Chronic Obstructive Pulmonary Disease Overlap in Routine Primary Care Practices. Annals of the American Thoracic Society, 2019, 16, 1143-1150.	1.5	32
69	Realâ€™life effectiveness of inhaler device switch from dry powder inhalers to pressurized metredâ€™dose inhalers in patients with asthma treated with ICS/LABA. Respiriology, 2019, 24, 972-979.	1.3	13
70	Diabetes mellitus comorbidity in patients enrolled in tuberculosis drug efficacy trials around the world: A systematic review. British Journal of Clinical Pharmacology, 2019, 85, 1407-1417.	1.1	12
71	The socioeconomic burden of chronic lung disease in low-resource settings across the globe â€™ an observational FRESH AIR study. Respiratory Research, 2019, 20, 291.	1.4	30
72	Making sense of cost-effectiveness analyses in respiratory medicine: a practical guide for non-health economists. European Respiratory Journal, 2019, 53, 1801816.	3.1	16

#	ARTICLE	IF	CITATIONS
73	An international perspective on hospitalized patients with viral community-acquired pneumonia. <i>European Journal of Internal Medicine</i> , 2019, 60, 54-70.	1.0	26
74	Does Changing Inhaler Device Impact Real-Life Asthma Outcomes? Clinical and Economic Evaluation. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 934-942.	2.0	12
75	High COPD prevalence at high altitude: does household air pollution play a role?. <i>European Respiratory Journal</i> , 2019, 53, 1801193.	3.1	42
76	Development of the International Severe Asthma Registry (ISAR): A Modified Delphi Study. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 578-588.e2.	2.0	39
77	HbA1c response after insulin initiation in patients with type 2 diabetes mellitus in real life practice: Identifying distinct subgroups. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1957-1964.	2.2	13
78	Addressing the Impact and Unmet Needs of Nonadherence in Asthma and Chronic Obstructive Pulmonary Disease: Where Do We Go From Here?. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 785-793.	2.0	63
79	The Clinical Impact of Different Adherence Behaviors in Patients with Severe Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 197, 1630-1633.	2.5	36
80	Asthma Cost-Effectiveness Analyses: Are We Using the Recommended Outcomes in Estimating Value?. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 619-632.	2.0	14
81	Diabetes mellitus and chronic kidney disease in the Eastern Mediterranean Region: findings from the Global Burden of Disease 2015 study. <i>International Journal of Public Health</i> , 2018, 63, 177-186.	1.0	30
82	Global Alliance for Chronic Disease researchers' statement on multimorbidity. <i>The Lancet Global Health</i> , 2018, 6, e1270-e1271.	2.9	43
83	Real-world effectiveness evaluation of budesonide/formoterol Spiromax for the management of asthma and chronic obstructive pulmonary disease in the UK. <i>BMJ Open</i> , 2018, 8, e022051.	0.8	3
84	Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2018, 391, 2236-2271.	6.3	638
85	Burden and risk factors for <i>Pseudomonas aeruginosa</i> community-acquired pneumonia: a multinational point prevalence study of hospitalised patients. <i>European Respiratory Journal</i> , 2018, 52, 1701190.	3.1	122
86	Personalising adherence-enhancing interventions using a smart inhaler in patients with COPD: an exploratory cost-effectiveness analysis. <i>Npj Primary Care Respiratory Medicine</i> , 2018, 28, 24.	1.1	30
87	Availability, use, and affordability of medicines in urban China under universal health coverage: an empirical study in Hangzhou and Baoji. <i>BMC Health Services Research</i> , 2018, 18, 218.	0.9	9
88	Cost-Effectiveness of Biological Asthma Treatments: A Systematic Review and Recommendations for Future Economic Evaluations. <i>Pharmacoeconomics</i> , 2018, 36, 957-971.	1.7	72
89	Alcohol use and burden for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2018, 392, 1015-1035.	6.3	2,005
90	The burden of disease in Greece, health loss, risk factors, and health financing, 2000–2016: an analysis of the Global Burden of Disease Study 2016. <i>Lancet Public Health, The</i> , 2018, 3, e395-e406.	4.7	37

#	ARTICLE	IF	CITATIONS
91	Why prescribe ICS to Dutch COPD patients in primary care, and when and how to stop. Data from focus groups with patients and health care providers. , 2018, , .		1
92	REducing Delay through edUcation on eXacerbations (REDUX) in patients with COPD. , 2018, , .		2
93	More household air pollution and COPD at higher altitude - a population-based, observational FRESH AIR study in rural Kyrgyzstan. , 2018, , .		0
94	The impact of asthma and/or COPD on work absence. , 2018, , .		0
95	Clinical characteristics, treatment patterns, and socio-economic burden of COPD in Bulgaria. Journal of Medical Economics, 2017, 20, 503-509.	1.0	13
96	Associations between chronic comorbidity and exacerbation risk in primary care patients with COPD. Respiratory Research, 2017, 18, 31.	1.4	91
97	Effectiveness and success factors of educational inhaler technique interventions in asthma & COPD patients: a systematic review. Npj Primary Care Respiratory Medicine, 2017, 27, 24.	1.1	90
98	Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990â€“2015: a novel analysis from the Global Burden of Disease Study 2015. Lancet, The, 2017, 390, 231-266.	6.3	480
99	In patients with severe uncontrolled asthma, does knowledge of adherence and inhaler technique using electronic monitoring improve clinical decision making? A protocol for a randomised controlled trial. BMJ Open, 2017, 7, e015367.	0.8	21
100	Urging Europe to put non-adherence to inhaled respiratory medication higher on the policy agenda: a report from the First European Congress on Adherence to Therapy. European Respiratory Journal, 2017, 49, 1700076.	3.1	33
101	Electric scooters: batteries in the battle against ambient air pollution?. Lancet Planetary Health, The, 2017, 1, e168-e169.	5.1	6
102	Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1084-1150.	6.3	573
103	Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1260-1344.	6.3	1,589
104	Global, regional, and national age-sex specific mortality for 264 causes of death, 1980â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1151-1210.	6.3	3,565
105	Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1211-1259.	6.3	5,578
106	Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1345-1422.	6.3	1,879
107	Measuring progress and projecting attainment on the basis of past trends of the health-related Sustainable Development Goals in 188 countries: an analysis from the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1423-1459.	6.3	284
108	Costly comorbidities of COPD: the ignored side of the coin?. European Respiratory Journal, 2017, 50, 1700917.	3.1	6

#	ARTICLE	IF	CITATIONS
109	Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990â€”2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet Respiratory Medicine</i> , 2017, 5, 691-706.	5.2	1,672
110	Optimizing identification and management of COPD patients â€” reviewing the role of the community pharmacist. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 192-201.	1.1	42
111	Systematic Review and Quality Appraisal of Cost-Effectiveness Analyses of Pharmacologic Maintenance Treatment for Chronic Obstructive Pulmonary Disease: Methodological Considerations and Recommendations. <i>Pharmacoeconomics</i> , 2017, 35, 43-63.	1.7	36
112	Indacaterol/glycopyrronium is cost-effective compared to salmeterol/fluticasone in COPD: FLAME-based modelling in a Swedish population. <i>Respiratory Research</i> , 2017, 18, 206.	1.4	5
113	Does co-payment for inhaler devices affect therapy adherence and disease outcomes? A historical, matched cohort study. <i>Journal of Pragmatic and Observational Research</i> , 2017, Volume 8, 31-41.	1.1	3
114	Asthma cost-effectiveness analyses: Are we using the recommended outcomes in estimating value?. , 2017, , .		1
115	Indacaterol/glycopyrronium (IND/GLY) is cost-effective compared with salmeterol/fluticasone (SFC) in Swedish chronic obstructive pulmonary disease (COPD) patients. , 2017, , .		0
116	Real-life evaluation of budesonide/formoterol (DuoResp Spiromax) for the management of asthma and COPD in the UK. , 2017, , .		0
117	Late Breaking Abstract - Health economic burden of asthma/COPD in Uganda, Vietnam, Kyrgyzstan and Greece: FRESH AIR results. , 2017, , .		0
118	Higher Adherence During Reimbursement of Pharmacological Smoking Cessation Treatments. <i>Nicotine and Tobacco Research</i> , 2016, 18, ntv064.	1.4	12
119	Cost-effectiveness and budget impact of the fixed-dose dual bronchodilator combination tiotropium–olodaterol for patients with COPD in the Netherlands. <i>International Journal of COPD</i> , 2016, Volume 11, 2191-2201.	0.9	16
120	Economic Evaluations of Pharmacogenetic and Pharmacogenomic Screening Tests: A Systematic Review. Second Update of the Literature. <i>PLoS ONE</i> , 2016, 11, e0146262.	1.1	94
121	Enhancing the use of Asthma and COPD Assessment Tools in Balearic Primary Care (ACATIB): a region-wide cluster-controlled implementation trial. <i>Npj Primary Care Respiratory Medicine</i> , 2016, 26, 16003.	1.1	11
122	Hollywood raising awareness of smoking-related diseases: can it proactively counteract the impact of smoking in movies?â€”the final mission of Star Trekâ€™s Mr Spock. <i>Npj Primary Care Respiratory Medicine</i> , 2016, 26, 16052.	1.1	0
123	What We Mean When We Talk About Adherence in Respiratory Medicine. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2016, 4, 802-812.	2.0	104
124	Enhancing Respiratory Medication Adherence: The Role of Health Care Professionals and Cost-Effectiveness Considerations. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2016, 4, 835-846.	2.0	64
125	Factors associated with inhaled corticosteroids prescription in primary care patients with COPD: A cross-sectional study in the Balearic Islands (Spain). <i>European Journal of General Practice</i> , 2016, 22, 232-239.	0.9	5
126	COPD case finding: effective, but also cost-effective?. <i>Lancet Respiratory Medicine</i> , 2016, 4, e49.	5.2	3

#	ARTICLE	IF	CITATIONS
127	Global initiative for meticillin-resistant <i>Staphylococcus aureus</i> pneumonia (GLIMP): an international, observational cohort study. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 1364-1376.	4.6	109
128	Cost comparison of asthma treatments in 12-week study: caution about matching and short observational follow-up. <i>Multidisciplinary Respiratory Medicine</i> , 2016, 11, 39.	0.6	0
129	Investigating the association between medication adherence and health-related quality of life in COPD: Methodological challenges when using a proxy measure of adherence. <i>Respiratory Medicine</i> , 2016, 110, 34-45.	1.3	18
130	Comorbidity, Pattern, and Impact of Asthma-COPD Overlap Syndrome in Real Life. <i>Chest</i> , 2016, 149, 1011-1020.	0.4	113
131	Effects of targeting disease and medication management interventions towards patients with COPD. <i>Current Medical Research and Opinion</i> , 2016, 32, 229-239.	0.9	17
132	Towards tailored and targeted adherence assessment to optimise asthma management. <i>Npj Primary Care Respiratory Medicine</i> , 2015, 25, 15046.	1.1	54
133	Predictors of cost-effectiveness of selected COPD treatments in primary care: UNLOCK study protocol. <i>Npj Primary Care Respiratory Medicine</i> , 2015, 25, 15051.	1.1	7
134	Mapping the Clinical Chronic Obstructive Pulmonary Disease Questionnaire onto Generic Preference-Based EQ-5D Values. <i>Value in Health</i> , 2015, 18, 299-307.	0.1	16
135	Medication Monitoring and Optimization: A Targeted Pharmacist Program for Effective and Cost-Effective Improvement of Chronic Therapy Adherence. <i>Journal of Managed Care Pharmacy</i> , 2014, 20, 786-792.	2.2	42
136	Improving Adherence to Lipid-Lowering Therapy in a Community Pharmacy Intervention Program: A Cost-Effectiveness Analysis. <i>Journal of Managed Care Pharmacy</i> , 2014, 20, 722-732.	2.2	22
137	Economic Evaluation of Ropinirole Prolonged Release for Treatment of Parkinson's Disease in The Netherlands. <i>Drugs and Aging</i> , 2014, 31, 193-201.	1.3	8
138	Proactive pharmaceutical care interventions decrease patients' nonadherence to osteoporosis medication. <i>Osteoporosis International</i> , 2014, 25, 1807-12.	1.3	33
139	Improving inhaler adherence in patients with Chronic Obstructive Pulmonary Disease: a cost-effectiveness analysis. <i>Respiratory Research</i> , 2014, 15, 66.	1.4	63
140	Clinical and economic impact of non-adherence in COPD: A systematic review. <i>Respiratory Medicine</i> , 2014, 108, 103-113.	1.3	176
141	Impact of multiple-dose versus single-dose inhaler devices on COPD patients' persistence with long-acting β_2 -agonists: a dispensing database analysis. <i>Npj Primary Care Respiratory Medicine</i> , 2014, 24, 14069.	1.1	16
142	The pharmacists' potential to provide targets for interventions to optimize pharmacotherapy in patients with asthma. <i>International Journal of Clinical Pharmacy</i> , 2013, 35, 1075-1082.	1.0	16
143	Inhaled Corticosteroids and the Occurrence of Oral Candidiasis: A Prescription Sequence Symmetry Analysis. <i>Drug Safety</i> , 2013, 36, 231-236.	1.4	61
144	Persistence with osteoporosis medication among newly-treated osteoporotic patients. <i>Journal of Bone and Mineral Metabolism</i> , 2013, 31, 562-570.	1.3	46

#	ARTICLE	IF	CITATIONS
145	Proactive Pharmaceutical Care Interventions Improve Patients' Adherence to Lipid-Lowering Medication. <i>Annals of Pharmacotherapy</i> , 2013, 47, 1448-1456.	0.9	32
146	COPD in the Working Age Population: The Economic Impact on Both Patients and Government. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2013, 10, 629-639.	0.7	40
147	Adherence to Statin Therapy and Attainment of LDL Cholesterol Targets in an Outpatient Population of Type 2 Diabetes Patients: Analysis in the DIAbetes and LiFestyle Cohort Twente (DIALECT). <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	1